Arecor Therapeutics plc (AIM:AREC)
London · Delayed Price · Currency is GBP · Price in GBX 62.50
0.00 (0.00%)
Jun 16, 2026, 8:00 AM GMT
Arecor Therapeutics Income Statement
Financials in millions GBP. Fiscal year is January - December.
Millions GBP. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 1.71 | 1.64 | 4.57 | 2.4 | 1.16 | |
Revenue Growth (YoY) | 4.32% | -64.07% | 90.30% | 107.51% | -31.80% |
Cost of Revenue | 0.45 | 0.72 | 3.32 | - | - |
Gross Profit | 1.27 | 0.92 | 1.25 | 2.4 | 1.16 |
Selling, General & Admin | 3.17 | 3.32 | 6.17 | 5.38 | 2.39 |
Research & Development | 2.69 | 3.04 | 5.4 | 8.61 | 5.39 |
Other Operating Expenses | -0.56 | -0.27 | -1.14 | -1.25 | -0.64 |
Operating Expenses | 5.31 | 6.1 | 10.43 | 12.74 | 7.14 |
Operating Income | -4.05 | -5.18 | -9.18 | -10.34 | -5.98 |
Interest Expense | -0.01 | -0.02 | -0.02 | -0.02 | -0.02 |
Interest & Investment Income | 0.07 | 0.1 | 0.28 | 0.11 | 0 |
Other Non Operating Income (Expenses) | - | - | 0.01 | - | - |
EBT Excluding Unusual Items | -3.98 | -5.09 | -8.9 | -10.25 | -6 |
Merger & Restructuring Charges | - | - | - | -0.17 | - |
Gain (Loss) on Sale of Assets | 4.98 | - | - | - | - |
Other Unusual Items | - | - | - | - | -0.95 |
Pretax Income | 0.99 | -5.09 | -8.9 | -10.42 | -6.95 |
Income Tax Expense | 0.06 | 0.07 | -0.35 | -1.16 | -0.78 |
Earnings From Continuing Operations | 0.93 | -5.16 | -8.55 | -9.26 | -6.17 |
Earnings From Discontinued Operations | -0.27 | -5.07 | - | - | - |
Net Income | 0.66 | -10.24 | -8.55 | -9.26 | -6.17 |
Net Income to Common | 0.66 | -10.24 | -8.55 | -9.26 | -6.17 |
Shares Outstanding (Basic) | 38 | 33 | 31 | 29 | 23 |
Shares Outstanding (Diluted) | 39 | 33 | 31 | 29 | 23 |
Shares Change (YoY) | 17.94% | 9.20% | 5.83% | 25.63% | 41.77% |
EPS (Basic) | 0.02 | -0.31 | -0.28 | -0.32 | -0.27 |
EPS (Diluted) | 0.01 | -0.31 | -0.28 | -0.32 | -0.27 |
Free Cash Flow | -2.46 | -9.34 | -5.99 | -11.08 | -5.52 |
Free Cash Flow Per Share | -0.06 | -0.28 | -0.20 | -0.38 | -0.24 |
Gross Margin | 73.86% | 55.93% | 27.36% | 100.00% | 100.00% |
Operating Margin | -236.00% | -315.03% | -200.63% | -430.34% | -516.15% |
Profit Margin | 38.74% | -623.01% | -187.05% | -385.35% | -532.73% |
Free Cash Flow Margin | -143.64% | -568.35% | -131.03% | -461.05% | -476.60% |
EBITDA | -3.93 | -4.96 | -8.88 | -10.14 | -5.9 |
EBITDA Margin | -229.17% | - | -194.18% | - | - |
D&A For EBITDA | 0.12 | 0.22 | 0.3 | 0.2 | 0.08 |
EBIT | -4.05 | -5.18 | -9.18 | -10.34 | -5.98 |
EBIT Margin | -236.00% | - | -200.63% | - | - |
Effective Tax Rate | 6.24% | - | - | - | - |